Medicinal Cannabis: what next for Brazil?
Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.
- Pharma: A Mexican tradeoff 30-09-2019
- Secondary patents: Moscow mewl 30-09-2019
- The future of precision medicine part 6: reimbursement 08-08-2019
- Shire Pharmaceuticals: A culture of excellence 21-05-2019
- Marketing authorisation: Splitting the bill 20-05-2019
Latest generics news
LSPN Europe: new challenges for drug patent owners in Russia
21-11-2019
Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Pfizer and Sun settle Bosulif dispute
06-11-2019
